Foralumab

Foralumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD3 epsilon
Clinical data
ATC code	none;
Identifiers
CAS Number	946415-64-1 ;
ChemSpider	none;
UNII	J43DL56H6M;
	(what is this?) (verify)

Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon.[1] Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.[2]. However foralumab did not show efficacy for Crohn's disease.[3]

References

World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
"Foralumab". Tiziana Life Sciences plc.
Giuffrida P, Di Sabatino A (September 2020). "Targeting T cells in inflammatory bowel disease". Pharmacological Research. 159: 105040. doi:10.1016/j.phrs.2020.105040. PMID 32585338.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.

[2] "Foralumab". Tiziana Life Sciences plc.

[pmid32585338-3] Giuffrida P, Di Sabatino A (September 2020). "Targeting T cells in inflammatory bowel disease". Pharmacological Research. 159: 105040. doi:10.1016/j.phrs.2020.105040. PMID 32585338.